One patient with NRAS, MPL positivity, FLT3/NPM1 WT had received 2 courses of high-dose cytarabine inductions with residual BM blast burden 80% and dural myeloid sarcoma. This evidence concerns the gene FLT3 and myeloid sarcoma.